Kaspersky Exits U.S., Automatically Replaces Software With UltraAV, Raising Concerns – OfficialSarkar

Sep 24, 2024Ravie LakshmananAntivirus / National Security

Kaspersky Exits U.S.

Antivirus vendor Kaspersky has formally begun pulling back its offerings in the U.S., migrating existing users to UltraAV, effective September 19, 2024, ahead of its formal exit at the end of the month.

“Kaspersky antivirus customers received a software update facilitating the transition to UltraAV,” the company said in a post announcing the move on September 21.

“This update ensured that users would not experience a gap in protection upon Kaspersky’s exit from the market.”

The Russian company, which was banned from selling its software in the U.S. due to national security concerns, said it “worked closely” with UltraAV to ensure that the standards of security and privacy were maintained after the switch.

Cybersecurity

However, some users who experienced the update have taken to Kaspersky’s forums and Reddit, stating that Kaspersky’s software was automatically deleted and replaced by UltraAV without any prior notice.

UltraAV, in an FAQ, said “all Kaspersky U.S. users with a valid email address associated with their accounts received email communication detailing the transition process” starting September 5.

However, it appears that the notice reportedly failed to explicitly state that the switch of software in user systems would be an automatic process.

“I was using Kaspersky, didn’t realize they’d be shuffling us off to some rando [antivirus] in September,” one user wrote in a post on Reddit. “Nearly had a heart attack when I started my PC today and found a program I didn’t download.”

A U.S. company, UltraAV is part of Pango Group, which also offers several other VPN apps like UltraVPN, OVPN, and VPN360. It touts more than 25 million active users across its brands, and over 650 million lifetime users.

Found this article interesting? Follow us on Twitter and LinkedIn to read more exclusive content we post.

Source: TheHackerNews

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *